Compare LUNG & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LUNG | TSI |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 221.5M |
| IPO Year | 2020 | 1995 |
| Metric | LUNG | TSI |
|---|---|---|
| Price | $1.31 | $4.55 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | ★ 511.9K | 111.4K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.46% |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $4.43 |
| 52 Week High | $3.88 | $5.06 |
| Indicator | LUNG | TSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 45.46 |
| Support Level | $1.27 | $4.54 |
| Resistance Level | $1.45 | $4.63 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 51.85 | 33.33 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.